North American Management’s Vertex Pharmaceuticals VRTX Stock Holding History

North American Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	–	Sell	-3,180	Closed	-$301K	–	138
2014 Q2	$301K	Sell	3,180 -2,550	-45%	-$179K	0.05%	121
2014 Q1	$405K	Hold	5,730	–	–	0.07%	108
2013 Q4	$426K	Hold	5,730	–	–	0.07%	104
2013 Q3	$434K	Buy	5,730 +635	+12%	+$50.5K	0.08%	93
2013 Q2	$408K	Buy	+5,095	New	+$375K	0.08%	93

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

North American Management's VRTX Position: Q3 2014 in Review

North American Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2014, closing a stake of 3,180 shares — an estimated $301K sold.

North American Management first reported a position in VRTX in Q2 2013 and held it in 5 quarters. The position peaked at $434K in Q3 2013. 431 funds tracked by Wall St. Rank hold VRTX as of Q3 2014.

North American Management reported no remaining Vertex Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
North American Management sold 3,180 Vertex Pharmaceuticals shares in Q3 2014, an estimated $301K.
North American Management first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 5 quarters.
North American Management's Vertex Pharmaceuticals position peaked at $434K in Q3 2013.
431 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2014.

Based on North American Management's 13F filing for Q3 2014, filed 3 Nov 2014.